myBiometry, a Lowell, MA-based asthma and COPD diagnostic and remote monitoring company, raised $5M in Seed Funding.
The round was led by Dexcom Ventures, with participation from CareSource Indiana, and Elevate Ventures.
The company intends to use the funds to advance the development of its fenoTRACK solution, a device designed to empower asthma and COPD patients by providing data to enable early detection of exacerbations.
Led by CEO Bryan Nolan, myBiometry aims to empower people with asthma and COPD to live healthier lives by providing them with proactive and actionable data to prevent attacks at home. fenoTRACK is a portable, non-invasive breath test that measures type 2 airway inflammation via fractional exhaled nitric oxide (FeNO).
myBiometry’s products are currently in development and have not yet been cleared by the FDA. The company also has operations in Indiana. The company is currently focused on completing the development of fenoTRACK and preparing for its regulatory submission.
FinSMEs
12/11/2024